Joseph Hagan is Chief Executive Officer of Regulus Therapeutics Inc. (RGLS). The company reported total compensation of $2,575,123 for fiscal year 2023.
| Salary | $615,800 |
|---|---|
| Bonus | $0 |
| Stock awards | $88,000 |
| Option awards | $1,528,091 |
| Non-equity incentive plan | $332,532 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $9,900 |
| Total | $2,575,123 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Regulus Therapeutics Inc. filed April 19, 2024, accession 0001193125-24-102883.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2023 | Chief Executive Officer | $615,800 | $0 | $88,000 | $1,528,091 | $332,532 | $0 | $9,900 | $2,575,123 |
| FY2022 | Chief Executive Officer | $597,875 | $0 | $102,800 | $319,710 | $322,853 | $0 | $0 | $1,343,238 |
Totals as disclosed in each year's own compensation disclosure for Regulus Therapeutics Inc..
| Named executive officer | Role | FY2023 total |
|---|---|---|
| Joseph Hagan this page | Chief Executive Officer | $2,575,123 |
| Christopher Aker | Senior Vice President and General Counsel | $1,085,087 |
| Cris Calsada | Chief Financial Officer | $1,068,174 |
The company's named executive officers for fiscal year 2023, and what it reported for each. See the full Regulus Therapeutics Inc. compensation brief.
Joseph Hagan's compensation sits inside Regulus Therapeutics Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.